<DOC>
	<DOCNO>NCT00014118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow radiation therapy chemotherapy treat patient stage III stage IV cancer larynx stage III stage IV cancer oropharynx .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Treating Patients With Stage III Stage IV Larynx Oropharynx Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine organ preservation rate patient stage III IV squamous cell carcinoma larynx oropharynx treat paclitaxel carboplatin follow paclitaxel concurrent radiotherapy . - Determine feasibility toxicity regimen patient . - Determine utility pre- post-treatment organ function instrument swallow ability voice quality patient treat regimen . - Determine disease-free survival pattern failure patient treat regimen . - Determine objective tumor response rate ( complete partial response ) patient follow treatment 2 course induction therapy paclitaxel carboplatin . - Determine change quality life patient treat regimen . - Determine whether presence human papilloma virus infection p-glycoprotein correlate outcome patient treated regimen . OUTLINE : This multicenter study . Patients stratify accord disease site ( larynx v oropharynx ) . Patients receive induction therapy comprise paclitaxel IV 3 hour follow carboplatin IV 30-60 minute day 1 22 . Within 28 day completion induction therapy , patient respond stable disease receive paclitaxel IV 60 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 radiotherapy daily , 5 time weekly , 7 week begin day 1 . Within 6-8 week completion therapy , patient initially bulky neck disease ( N3 ) residual palpable lymphadenopathy undergo surgical neck dissection . Patients N1-N2 disease complete response may also undergo neck dissection . Patients initial complete response recur primary site undergo surgical salvage . Quality life assess baseline , induction therapy , 3 , 12 , 24 month completion therapy . Patients follow 6 week , 3 month , every 6-8 week 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month 5 year thereafter . PROJECTED ACCRUAL : A total 110 patient ( 55 per stratum ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ( T2T4 ) squamous cell carcinoma larynx oropharynx No recurrent disease No evidence distant metastasis Resectable disease , define follow : High probability attain clear surgical margin ( disease base tongue , tonsil , soft palate , pharyngeal wall ) No extension root tongue ( disease base tongue ) No extension pterygoid radiograph ( disease tonsil , soft palate , pharyngeal wall ) No primary tumor nodal metastases fix carotid artery cervical spine ( disease base tongue , tonsil , soft palate , pharyngeal wall ) No trismus ( disease tonsil , soft palate , pharyngeal wall ) No involvement trachea great 1 cm involvement esophagus ( disease subglottis ) For disease supraglottis , glottis , subglottis : No base tongue invasion great 2 cm No tumor extension cartilage involve strap muscle neck No tumor fixation prevertebral fascia No involvement carotid artery No fix nodal disease involvement deep neck Extension pyriform sinus lateral pharyngeal wall allow extension posterior pharynx Measurable disease Lesions accurately measure least one dimension &gt; 20 mm ( 2.0 cm ) conventional technique &gt; 10 mm ( 1.0 cm ) spiral CT scan Cytologic histologic evidence neoplasm need measurable disease restrict solitary lesion No concurrent head neck neoplasms PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Not specify Renal Creatinine le 3.0 mg/dL Calcium normal Cardiovascular No significant cardiac disease No uncontrolled hypertension No unstable angina No congestive heart failure No myocardial infarction within past year No serious cardiac arrhythmia require medication Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study completion No significant detectable infection No history allergy drug contain Cremophor EL No history allergy mammalian cellderived product ( epoetin alfa ) human albumin No malignancy within past 3 year except basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy No concurrent amifostine Endocrine therapy Not specify Radiotherapy No prior radiotherapy clavicle Surgery No prior surgery primary tumor except biopsy debulking Other No concurrent experimental mucosal protectants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>